Abstract
Background As investigator site audits have largely been conducted remotely during the COVID-19 pandemic, remote quality monitoring has gained some momentum. To further facilitate the conduct of remote Quality Assurance (QA) activities for clinical trials, we developed new quality indicators, building on a previously published statistical modeling methodology.
Methods We modeled the risk of having an audit or inspection finding using historical audits and inspections data from 2011 - 2019. We used logistic regression to model finding risk for 4 clinical impact factor (CIF) categories: Safety Reporting, Data Integrity, Consent and Protecting Endpoints.
Results We could identify 15 interpretable factors influencing audit finding risk of 4 out of 5 CIF categories. They can be used to realistically predict differences in risk between 25 and 43% for different sites which suffice to rank sites by audit and inspection finding risk.
Conclusion Continuous surveillance of the identified risk factors and resulting risk estimates could be used to complement remote QA strategies for clinical trials and help to manage audit targets and audit focus also in post-pandemic times.
Competing Interest Statement
Björn Koneswarakantha and Timothé Ménard were employed by Roche at the time this research was conducted.
Funding Statement
Development of the statistical model was funded by Roche.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Compliance with Ethical Standards
Funding Development of the statistical model was funded by Roche.
Conflict of Interest Björn Koneswarakantha and Timothé Ménard were employed by Roche at the time this research was conducted.
Ethics approval All human subject data used in this analysis were used in a de-identified format. Ethics approval is not applicable.
Code availability https://github.com/openpharma/quality_risk_assesment_clinical_trials
All sections of the manuscript have been revised for further clarifications on the study scope and objectives.
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
https://github.com/openpharma/quality_risk_assesment_clinical_trials
